Moderna Provides Update on Norovirus Vaccine Candidate
Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial investigating a vaccine candidate for norovirus in a company statement on Monday.
Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.
Vaxart (VXRT) provided business updates as the Company continues to advance its oral pill vaccine platform. COVID-19 Phase 2b study poised to ...
Within hours, I was hunched over the toilet. By late afternoon, one of our weekend guests had also succumbed. Then came a text from my cousin, who, along with her husband, babysat my son recently: “It ...
There’s no medication for norovirus. Instead, you’ll need to rehydrate as much as possible with water and other liquids. Seek ...
There is currently no vaccine for norovirus because of its many strains and the elusive nature of how the virus evolves. The closest norovirus vaccine is a Moderna trial wrapping up in 2027 ...
Symptoms of norovirus typically develop within 12 to 48 hours after exposure, the most common symptoms being diarrhea, ...
COVID-19 Phase 2b study poised to initiate 10,000 participant portion of trial pending U.S. Food and Drug Administration (FDA) review of sentinel ...
A stomach illness outbreak at the University of Guelph is part of a trend that has experts noticing a rise in stomach bugs causing vomiting and diarrhea.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback